Kintara Therapeutics to Participate in Maxim Group's 2021 Emerging Growth Virtual Conference
Kintara Therapeutics, Inc. (Nasdaq: KTRA) announced that CEO Saiid Zarrabian will participate in Maxim Group's 2021 Emerging Growth Virtual Conference on March 17-18, 2021. Zarrabian will speak on glioblastoma treatments at 9:30 am ET, with an archived replay available later. Kintara is focused on developing therapies for rare cancers, with two Phase 3-ready projects: VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. VAL-083 has shown clinical activity in various cancers, while REM-001 has an 80% complete response rate in previous studies.
- None.
- None.
SAN DIEGO, March 10, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announces that its Chief Executive Officer Saiid Zarrabian will participate in Maxim Group's 2021 Emerging Growth Virtual Conference taking place March 17-18, 2021. Mr. Zarrabian will be a speaker on a panel discussing glioblastoma and, more specifically, chemo-based and/or DNA repair target solutions.
Investors can view Mr. Zarrabian's panel participation at 9:30 am ET on March 17, 2021 once they register for the conference here, and an archived replay of the panel discussion will be available on the conference website. Investors can also request a 1x1 meeting with Mr. Zarrabian to be arranged following the conclusion of the conference.
About Kintara
Located in San Diego, California, Kintara (Nasdaq: KTRA) is dedicated to the development of novel cancer therapies for patients with rare unmet medical needs. Kintara is currently developing two Phase 3-ready therapeutics, VAL-083 for glioblastoma multiforme (GBM) and REM-001 for cutaneous metastatic breast cancer (CMBC).
VAL-083 is a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of VAL-083 in GBM.
REM-001 is a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy of
For more information, please visit www.kintara.com or follow us on Twitter at @Kintara_Thera, Facebook and Linkedin.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials and the GBM AGILE study. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company's operations and clinical trials; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2020, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.
CONTACTS
Investors
CORE IR
516-222-2560
ir@coreir.com
Media
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/kintara-therapeutics-to-participate-in-maxim-groups-2021-emerging-growth-virtual-conference-301244290.html
SOURCE Kintara Therapeutics
FAQ
When will Kintara Therapeutics participate in the Maxim Group's 2021 Emerging Growth Conference?
Who is the speaker representing Kintara at the conference?
What time will Kintara's CEO speak at the conference?
What are the key products Kintara Therapeutics is developing?
What is the clinical activity of VAL-083?
What is the efficacy of REM-001 in previous studies?
Where can investors find more information about Kintara Therapeutics?
